#USA #Rockville #gene therapy #AAVnerGene #AAVone

AAVnerGene Unveils AAVone®2.1: Revolutionizing AAV Production

In an exciting development for the biotechnology sector, AAVnerGene Inc., based in Rockville, Maryland, has announced the launch of its cutting-edge AAVone®2.1 platform. This innovative single-plasmid AAV production system promises to significantly boost productivity, enhance full-capsid yield, and improve manufacturing efficiency—all while reducing costs. With the ability to produce approximately 1x10^16 genome copies (GC) per liter and achieving a remarkable >70% full capsids at harvest, the AAVone®2.1 sets a new standard for AAV vector production.

Transition from Multi-Plasmid to Single-Plasmid

The evolution from AAVone®1.0 to AAVone®2.1 marks a significant shift in AAV production technology. Traditional multi-plasmid systems have long been hampered by high proportions of empty capsids, which detract from the effectiveness of gene therapies. In contrast, the AAVone®2.1 platform efficiently minimizes this issue, showcasing improved performance across various AAV serotypes and compatibility with HEK293-based cell lines. This advancement not only lowers the plasmid requirement but also reduces culture volumes, purification workloads, processing steps, and overall manufacturing costs.

Addressing Challenges in Gene Therapy Production

The challenges in AAV manufacturing remain a critical concern within the field of gene therapy. Qizhao Wang, Ph.D., Chief Technology Officer of AAVnerGene, highlighted that while traditional multi-plasmid systems have facilitated advancements in the past, their limitations in productivity, the burden of empty capsids, and the complexity of purification remain significant hurdles in the pathway to commercialization. The introduction of AAVone®2.1 aims to tackle these obstacles, presenting a streamlined solution that enhances vector productivity and increases the full-capsid ratio.

Moreover, the potential for simplified manufacturing processes is expected to play a vital role in facilitating the clinical and commercial scalability of AAV-based gene therapy programs.

Expert Insights on AAVone®2.1

Daozhan Yu, CEO of AAVnerGene, expressed enthusiasm about the platform's capabilities, stating, "AAV gene therapy has been facing hurdles related to manufacturing costs, vector quality, and process scalability. With AAVone®2.1, we are optimistic that we can simplify and optimize AAV manufacturing, paving the way for broader clinical applications and commercial viability of various AAV gene therapy programs."

AAVnerGene's partnerships have already begun to bear fruit, with several organizations utilizing the AAVone®2.1 technology to advance their AAV gene therapy programs. The company is committed to providing groundbreaking technologies that alleviate manufacturing bottlenecks while simultaneously lowering development costs. This initiative plays a crucial role in expanding access to gene therapies, ultimately benefiting more patients in need.

A Look at AAVnerGene Inc.

AAVnerGene is dedicated to developing innovative solutions targeting the bottlenecks in AAV gene therapy, which include challenges related to production, toxicity, qualification, and delivery. The company’s technology portfolio comprises not only AAVone® but also AAV-Q (a potency and rcAAV assay platform) and ATHENA (a capsid engineering platform), all designed with the goal of enhancing efficiency, quality, scalability, and safety in the drug development landscape of AAV gene therapy.

With the unveiling of AAVone®2.1, AAVnerGene reaffirms its position as a leader in the biotech industry, committed to turning innovative ideas into practical solutions that advance the potential of gene therapy, helping more treatments reach patients in need.